Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily inhaled molgramostim in adult autoimmune pulmonary alveolar proteinosis
jRCT2051210036Recruiting
- Sponsor
- Savara
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial in autoimmune pulmonary alveolar proteinosis (aPAP) comparing Molgramostim arm with Placebo arm (2 arms). Primary endpoint: Change in percent predicted DLCO from baseline to Week 24. Started Jul 2021; status: recruiting.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on jRCT2051210036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210036.